Probability of allogeneic hematopoietic stem cell transplant failure depending on the recipient's killer immunoglobulin-like receptor genotype

Introduction. Natural killers are the "first line" of antitumor and antiviral protection in the early stages after аllogeneic hematopoietic stem cell transplantation. Quantitative characteristics reach normal values already in the first month after the infusion of blood stem cells to the recipient. Self-tolerance of natural killers is achieved due to many receptors on their surface, but killer immunoglobulin-like receptors play a key role. Their role is to recognize "self" cells and block signals aimed at destroying their own cells. Knowledge of the functional activity of natural killers urged to studying the impact of mismatches between the inhibitory receptor gene and the ligand on the development of allogeneic hematopoietic stem cell transplant failure.
The aim of research was to study the probability of the graft failure development in allogeneic hematopoietic stem cell transplantation depending on the recipient's killer immunoglobulin-like receptor genotype.
Material and methods. Genotyping of killer-cell immunoglobulin-like receptors in 66 recipients of blood stem cells by the polymerase chain reaction method was performed in the study. Using an online calculator, receptors were classified as "best", "better" and "neutral" depending on the genotype. The end point of the assessment was the development of graft failure in the presence of different genotypes of immunoglobulin-like receptors in the recipient.
Results. According to the data obtained, the presence of the “best” and "better" killer-cell immunoglobulin-like receptor genotype in the recipient significantly increased the risks of developing various forms of graft failure.
Conclusion. The presence of the KIR2DL3 genotype in a recipient of hematopoietic stem cells significantly (by 3 times) reduces the likelihood of primary graft failure. This result is of great prognostic significance, although at present no ways of influencing it have been developed. The presence of the “best” killer immunoglobulin-like receptors genotype in the recipient increases the likelihood of developing graft failure by more than 3 times compared to the best and neutral genotype (44.4% vs. 13.4%).

1. Becker PS, Suck G, Nowakowska P, Ullrich E, Seifried E, Bader P, et al. Selection and expansion of natural killer cells for NK cell-based immunotherapy. Cancer Immunol Immunother. 2016;65(4):477–484. PMID: 26810567 https://doi.org/10.1007/s00262-016-1792-y

2. Raulet DH, Vance RE. Self-tolerance of natural killer cells. Nat Rev Immunol. 2006;6(7):520–531. PMID: 16799471 https://doi.org/10.1038/nri1863

3. Mikhaltsova ED, Popova NN, Drokov MYu, Kapranov NM, Davydova YuO, Vasilieva VA, et al. Impact of graft-versus-host disease prophylaxis on immune reconstitution in patients after allogeneic hematopoietic stem cell transplantation. Medical Immunology (Russia). 2021;23(5):1125–1136. (In Russ.). https://doi.org/10.15789/1563-0625-IOG-2167

4. Melkova KN, Sharoyan ZhV, Frolov GP. Natural killer cells: license to kill. Clinical oncohematology. 2020;13(3):273–9 (In Russ.). https://doi.org/10.21320/2500-2139-2020-13-3-273-279

5. Ullah MA, Hill GR, Tey SK. Functional reconstitution of natural killer cells in allogeneic hematopoietic stem cell transplantation. Front Immunol. 2016;7:144. PMID: 27148263 https://doi.org/10.3389/fimmu.2016.00144 eCollection 2016.

6. Mikhaltsova E, Drokov MY, Davydova JO, Kuzmina LA, Popova N, Dubnyak D, et al. Impact of post-transplant high-dose cyclophosphamide on reconstitution in bone marrow recipients. Blood. 2017;130(Suppl 1):5485. https://doi.org/10.1182/blood.V130.Suppl_1.5485.5485

7. Bignon JD, Gagne K. KIR matching in hematopoietic stem cell transplantation. Curr Opin Immunol. 2005;17(5):553–559. PMID: 16085405 https://doi.org/10.1016/j.coi.2005.07.014

8. Zhao XY, Yu XX, Xu ZL, Cao XH, Huo MR, Zhao XS, et al. Donor and host coexpressing KIR ligands promote NK education after allogeneic hematopoietic stem cell transplantation. Blood Adv. 2019;3(24):4312–4325. PMID: 31869417 https://doi.org/10.1182/bloodadvances.2019000242

9. Kärre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature. 1986;319(6055):675–678. PMID: 3951539 https://doi.org/10.1038/319675a0

10. Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood. 2001;97(10):3146–3151. PMID: 11342442 https://doi.org/10.1182/blood.v97.10.3146

11. Montaldo E, Del Zotto G, Della Chiesa M, Mingari MC, Moretta A, De Maria A, et al. Human NK cell receptors/markers: a tool to analyze NK cell development, subsets and function. Cytometry A. 2013;83(8):702–713. PMID: 23650273 https://doi.org/10.1002/cyto.a.22302

12. Mancusi A, Ruggeri L, Urbani E, Pierini A, Massei MS, Carotti A, et al. Haploidentical hematopoietic transplantation from KIR ligand-mismatched donors with activating KIRs reduces nonrelapse mortality. Blood. 2015;125(20):3173–3182. PMID: 25769621 https://doi.org/10.1182/blood-2014-09-599993

13. Moesta AK, Parham P. Diverse functionality among human NK cell receptors for the C1 epitope of HLA-C: KIR2DS2, KIR2DL2, and KIR2DL3. Front Immunol. 2012;3:336. PMID: 23189078 https://doi.org/10.3389/fimmu.2012.00336 eCollection 2012

14. Khamaganova EG, Parovichnikova EN, Kuzmina LA, Kulikov SM, Kuzminova EP, Yushkova AA, et al. Effects of killer immunoglobulin-like receptor genes and their HLA ligands on survival of patients with acute myeloid leukemias after allogenic hemopoietic stem cell transplantation. Russian journal of hematology and transfusiology. 2015;60(3):16–21. (In Russ.).

15. Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Le CT, et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood. 2010;116(14):2411-2419. PMID: 20581313 https://doi.org/10.1182/blood-2010-05-283051

16. Barao I, Murphy WJ. The immunobiology of natural killer cells and bone marrow allograft rejection. Biol Blood Marrow Transplant. 2003;9(12):727–741. PMID: 14677112 https://doi.org/10.1016/j.bbmt.2003.09.002

17. Murphy WJ, Reynolds CW, Tiberghien P, Longo DL. Natural killer cells and bone marrow transplantation. J Natl Cancer Inst. 1993;85(18):1475–1482. PMID: 8360930 https://doi.org/10.1093/jnci/85.18.1475

18. Li L, Kolk M, Fernandez-Vina M, de Lima M, Otegbeye F. Interrogating the impact of KIR ligand mismatch in engraftment following HLA-disparate stem cell transplantation. Bone Marrow Transplant. 2020;55(12):2294–2297. PMID: 32461586 https://doi.org/10.1038/s41409-020-0957-7

19. Maruyama K, Aotsuka N, Kumano Y, Sato N, Kawashima N, Onda Y, et al. Immune-mediated hematopoietic failure after allogeneic hematopoietic stem cell transplantation: a common cause of late graft failure in patients with complete donor chimerism. Biol Blood Marrow Transplant. 2018;24(1):43–49. PMID: 28860001 https://doi.org/10.1016/j.bbmt.2017.08.018